natgillin/translations-raw huggingface dataset:
The tablets are white to off-white, of round shape, with bevelled edges, and have a code embossed (one side with the code P2, and one side with the Boehringer Ingelheim company symbol).
Tablete so bele do skoraj bele, okrogle, z zaobljenim robom in imajo vtisnjeno oznako (na eni strani je oznaka P2, na drugi pa znak podjetja Boehringer Ingelheim).
The tablets are white to off-white, round, convex and debossed with the number ‘15’ on one side and ‘TEVA’ on the other side.
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »15« na eni strani in »TEVA« na drugi strani.
The tablets are white to off-white, round, convex and debossed with the number ‘30’ on one side and ‘TEVA’ on the other side.
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »30« na eni strani in »TEVA« na drugi strani.
The tablets are white to off-white, round, convex and debossed with the number ‘45’ on one side and ‘TEVA’ on the other side.
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »45« na eni strani in »TEVA« na drugi strani.
The tablets are white to off-white, round, convex and marked ‘15’ on one face and ‘ACTOS’ on the other face.
Tablete so bele ali skoraj bele barve, okrogle, izbočene, z oznako ‘15’ na eni in ‘ACTOS’ na drugi strani.
The tablets are white to off-white, round, convex and marked ‘15’ on one face, ‘AD4’ on the other.
Tablete so bele ali skoraj bele barve, okrogle, izbočene, z oznako ‘15’ na eni in AD4 na drugi strani.
The tablets are white to off-white, round, flat and marked ‘30’ on one face and ‘ACTOS’ on the other face.
Tablete so bele ali skoraj bele barve, okrogle, ploščate, z oznako ‘30’ na eni in ‘ACTOS’ na drugi strani.
The tablets are white to off-white, round, flat and marked ‘30’ on one face, ‘AD4’ on the other.
Tablete so bele ali skoraj bele barve, okrogle, ploščate, z oznako ‘30’ na eni in AD4 na drugi strani.
The tablets are white to off-white, round, flat and marked ‘45’ on one face and ‘ACTOS’ on the other face.
Tablete so bele ali skoraj bele barve, okrogle, ploščate, z oznako ‘45’ na eni in ‘ACTOS’ na drugi strani.
The tablets are white to off-white, round, flat and marked ‘45’ on one face, ‘AD4’ on the other.
Tablete so bele ali skoraj bele barve, okrogle, ploščate, z oznako ‘45’ na eni in AD4 na drugi strani.
The tablets are white, flat, of round shape, scored on both sides, and have a code embossed (one side with the code P11, and one side with the Boehringer Ingelheim company symbol).
Tablete so bele, ploščate, okrogle, z zarezo na obeh straneh in imajo vtisnjeno oznako (na eni strani je oznaka P11, na drugi pa znak podjetja Boehringer Ingelheim).
The tablets are white, round and biconvex with bevelled edges.
Tablete so bele, okrogle in izbočene s posnetim robom.
The tablets are white, round and biconvex with bevelled edges.
Tablete so bele, okrogle in izbočene, s posnetim robom.
The tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved with ‘TZ15’ on one side.
Tablete so bele barve in okrogle oblike, na obeh straneh izbočene, imajo premer 5,5 mm in na eni strani vtisnjeno oznako ‘TZ15’.
The tablets are white, round, flat, bevelled, 7 mm in diameter and engraved with ‘TZ30’ on one side.
Tablete so bele barve in okrogle oblike, na obeh straneh izbočene, imajo premer 7 mm in na eni strani vtisnjeno oznako ‘TZ30’.
The tablets are white, round, flat, bevelled, 8 mm in diameter and engraved with ‘TZ45’ on one side.
Tablete so bele barve in okrogle oblike, na obeh straneh izbočene, imajo premer 8 mm in na eni strani vtisnjeno oznako ‘TZ45’.
The tablets can be divided into equal doses and can be taken with or without food.
Tablete lahko razdelite na dva enaka odmerja in ju lahko jemljete s hrano ali brez nje.
The tablets can be divided into equal halves.
Tablete lahko razpolovimo na dva enaka dela.
The tablets can be taken with or without a meal at any time of the day.
Tablete je mogoče vzeti s hrano ali brez nje in ob kateremkoli času dneva.
The tablets can be taken with or without food.
Tablete se lahko zaužijejo s hrano ali brez nje.
The tablets have a 20 mm diameter and a thickness of 6.5 mm.
Tablete imajo premer 20 mm in debelino 6,5 mm.
The tablets have ‘ESL 200’engraved on one side and are scored on the other side.
Tablete imajo vtisnjen napis ‘ESL 200’ na eni strani in zarezo na drugi.
The tablets have ‘ESL 400’engraved on one side and are scored on the other side.
Na eni strani je vtisnjen napis ‘ESL 400’, na drugi pa je zareza.
The tablets have ‘ESL 600’engraved on one side and are scored on the other side, enabling the tablets to be divided into equal halves.
Tablete imajo vtisnjen napis ‘ESL 600’ na eni strani in zarezo na drugi, ki omogoča delitev tablete na enaki polovici.
The tablets have ‘ESL 600’engraved on one side and are scored on the other side.
Tablete imajo vtisnjen napis ‘ESL 600’ na eni strani in zarezo na drugi.
The tablets have ‘ESL 800’engraved on one side and are scored on the other side, enabling the tablets to be divided into equal halves.
Tablete imajo vtisnjen napis ‘ESL 800’ na eni strani in zarezo na drugi, ki omogoča delitev tablete na enaki polovici.
The tablets have ‘ESL 800’engraved on one side and are scored on the other side.
Tablete imajo vtisnjen napis ‘ESL 800’ na eni strani in zarezo na drugi.
The tablets must be dispersed in a minimum of 5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric tube.
Tablete je treba dispergirati v najmanj 5–10 ml vode in takoj zaužiti, ali aplicirati s hitrim vbrizganjem skozi nazogastrično sondo.
The tablets must be swallowed whole.
Tablete je treba pogoltniti cele.
The tablets must be swallowed whole.
Tablete morate pogoltniti cele.
The tablets must be taken in three divided doses each day.
Tablete je treba vzeti v treh deljenih odmerkih vsak dan.
The tablets must be taken whole and are not to be divided.
Tablete morate vzeti cele in jih ne smete prelomiti.
The tablets must be taken with a glass of water within 1 hour after completion of the morning and evening meals.
Tablete morate vzeti s kozarcem vode v 1 uri po koncu jutranjega in večernega obroka.
The tablets must not be chewed, broken or crushed.
Tablet ni dovoljeno žvečiti, lomiti ali drobiti.
The tablets must not be split or cut.
Tablet ne smete lomiti ali rezati.
The tablets or the granules should be taken at 12-hour intervals with fat-containing foods, such as meals prepared with butter or oils or foods containing eggs, cheese, nuts, whole milk or meat.
Tablete ali zrnca je treba vzeti v razmiku 12 ur skupaj s hrano, ki vsebuje maščobo, kot je hrana, pripravljena z maslom ali oljem, ali hrana, ki vsebuje jajca, sir, orehe, polnomastno mleko ali meso.
The tablets should be administered for at least 2 days beyond the cessation of clinical signs.
Tablete dajemo vsaj še dva dni po prenehanju kliničnih znakov bolezni.
The tablets should be administered with a meal as a single daily dose, to increase the absorption, and at the same time each day preferably in the morning.
Tablete mora bolnik vzeti v enkratnem dnevnem odmerku ob obroku, kar poveča absorbcijo, vsak dan ob istem času, najbolje zjutraj.
The tablets should be kept in the original package until use in order to prevent children directly accessing the medicine.
Tablete je treba do uporabe hraniti v originalni embalaži, da bi preprečili, da do njih neposredno dostopajo otroci.
The tablets should be swallowed whole at the same time every day and should not be chewed or crushed.
Tablete je treba pogoltniti cele ob istem času vsak dan in se ne smejo žvečiti ali zdrobiti.
The tablets should be swallowed whole with a drink of water.
Tableto pogoltnite celo s požirkom vode.
The tablets should be swallowed whole with a full glass of water (180 to 240 ml) while the patient is standing or sitting in an upright position.
Tablete je treba pogoltniti cele in popiti poln kozarec vode (180 do 240 ml); bolnik mora pri tem stati ali vzravnano sedeti.
The tablets should be swallowed whole with a full glass of water (180 to 240 ml) while the patient is standing or sitting in an upright position.
Tablete je treba pogoltniti cele s polnim kozarcem navadne vode (180 do 240 ml), bolnik mora pri tem stati ali sedeti pokončno.
The tablets should be swallowed whole with a full glass of water (180 to 240 ml) while the patient is standing or sitting in an upright position.
Tablete je treba pogoltniti cele s polnim kozarcem vode (180 do 240 ml), bolnik mora pri tem stati ali sedeti pokončno.
The tablets should be swallowed whole with half a glass of water.
Tablete je treba zaužiti cele s pol kozarca vode.
The tablets should be swallowed whole, and not chewed, crushed or divided.
Bolnik mora tablete zaužiti cele in jih ne sme grizti, drobiti ali lomiti.
The tablets should be swallowed with water at the same time each day.
Tablete je treba pogoltniti z vodo vsak dan ob isti uri.
The tablets should be taken by mouth and can be taken with or without food.
Lahko jo jemljete s hrano ali brez nje.
The tablets should be taken orally, swallowed with water, and can be taken either with or without food.
Bolniki naj tablete jemljejo peroralno, pogoltnejo naj jih s požirkom vode, lahko ob obrokih hrane ali brez njih.
The tablets should be taken whole and the suspension should be taken within 30 minutes of being prepared.
Tablete je treba pogoltniti cele, suspenzijo pa je treba vzeti v 30 minutah po pripravi.
The tablets should be taken whole, with food, in the evening or at bedtime.
Tablete Pelzont mora bolnik vzeti cele, s hrano, zvečer ali pred spanjem.
The tablets should be taken without food (see section 5.2).
Tablete se morajo jemati brez hrane (glejte poglavje 5.2).
The tablets should be taken without food.
Tablete se morajo jemati brez hrane.
The tablets should ideally be swallowed without crushing.
Tablete zdravila Combivir je najbolje pogoltniti cele, ne da bi jo prej zdrobili.
The tablets should not be chewed, crushed or split due to anticipated changes in the pharmacokinetic profile
Zaradi predvidenih sprememb farmakokinetičnega profila se tablet ne sme žvečiti, drobiti ali lomiti.
The tablets should not be divided or broken.
Tablete ne smete deliti ali zdrobiti.
The tablets were studied over five to six days in cats with acute musculoskeletal disorders and for up to one year in dogs with osteoarthritis.
Jemanje tablet so pet do šest dni proučevali na mačkah z akutnimi kostno-mišičnimi obolenji in do enega leta na psih z osteoartritisom.
The tabulation below includes all adverse reactions in clinical trials where adverse events were considered related.
V spodnji preglednici so navedene vse neželene reakcije v kliničnih preskušanjih, v katerih so neželene učinke opredelili kot povezane z zdravilom.
The tabulation below includes all adverse reactions in clinical trials where adverse events were considered related..
V spodnji preglednici so navedene vse neželene reakcije v kliničnih preskušanjih, v katerih so neželene učinke opredelili kot povezane z zdravilom.
The target audience and the modalities for distribution of all of these materials are to be agreed at Member State Level.
Glede ciljne publike in načina distribucije vseh teh gradiv se je treba uskladiti na ravni države članice.
The target dose of 28 mcg/day was administered in cycle 2 and subsequent cycles starting on day 1 of each cycle.
Ciljni odmerek 28 mcg/dan so v 2. in nadaljnjih ciklusih uporabljali od 1. dne vsakega ciklusa.
The target for trough concentrations was 10-20 ng/mL.
Tarčna najnižja koncentracija učinkovine v stanju dinamičnega ravnovesja je bila 10-20 ng/ml.
The target haemoglobin concentration in two studies was > 13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljna koncentracija hemoglobina v dveh študijah je bila > 13 g/dl, v drugih treh pa 12–14 g/dl.
The target haemoglobin concentration in two studies was > 13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljne koncentracije hemoglobina so bile v dveh študijah > 13 g/dl, v preostalih treh pa 1214 g/dl.
The target haemoglobin concentration in two studies was >13 g/dl; in the remaining three studies it was 12- 14 g/dl.
Ciljne koncentracije hemoglobina so bile v dveh študijah > 13 g/dl, v preostalih treh pa 1214 g/dl.
The target haemoglobin concentration in two studies was >13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljne koncentracije hemoglobina so bile v dveh študijah > 13 g/dl, v preostalih treh pa 1214 g/dl.
The target plasma mitotane concentration (14 mg/l) was reached in all patients within 3 to 5 months and the total mitotane dose ranged between 283 and 387 g (median value: 363 g).
Ciljna plazemska koncentracija mitotana (14 mg/l) je bila dosežena pri vseh bolnikih v 3 do 5 mesecih, pri čemer je bil skupen odmerek mitotana v območju 283 do 387 g (mediana vrednost:
The targeted maintenance dose is 1.3 gram/m2/day, in two divided doses, given every 12 hours.
Ciljni vzdrževalni odmerek je 1,3 grama/m2/dan, ki se ga daje v dveh deljenih odmerkih v razmiku 12 ur.
The targeted maintenance dose is 1.3 gram/m2/day.
Ciljni vzdrževalni odmerek je 1,3 grama/m2/dan.
The targeted maintenance dose of 1.3 g/m2/day can be approximated according to the following table, which takes surface area as well as weight into consideration.
Odmerek, ki približno ustreza ciljnemu vzdrževalnemu odmerku 1,3 g/m2/dan, je mogoče določiti s pomočjo spodnje preglednice, kjer sta upoštevani tako površina kot telesna masa.
The TAXOTERE 20 mg/0.5 ml vial contains a solution of docetaxel in polysorbate 80 at a concentration of 40 mg/ml.
Viala zdravila TAXOTERE 20 mg/0,5 ml vsebuje raztopino docetaksela v polisorbatu 80 v koncentraciji 40 mg/ml.
The TAXOTERE 20 mg/0.5 ml vial is a 7 ml clear glass vial with a green flip-off cap.
Viala zdravila TAXOTERE 20 mg/0,5 ml je 7-ml viala iz prozornega stekla z zeleno dvižno zaporko.
The TAXOTERE 80 mg/2 ml vial contains a solution of docetaxel in polysorbate 80 at a concentration of 40 mg/ml.
Viala zdravila TAXOTERE 80 mg/2 ml vsebuje raztopino docetaksela v polisorbatu 80 v koncentraciji 40 mg/ml.
The TAXOTERE 80 mg/2 ml vial is a 15 ml clear glass vial with a red flip-off cap.
Viala zdravila TAXOTERE 80 mg/2 ml je 15-ml viala iz prozornega stekla z rdečo dvižno zaporko.
The Techne DB-3 Dri Block Heater is fully validated for use in the constitution of Myocet.
Grelec Techne DB-3 Dri Block je v celoti validiran za uporabo pri konstituciji zdravila Myocet.
The technical data are given only for information and should not limit health-care providers’ choice.
Tehnični podatki so navedeni samo v informacijo in ne smejo ovirati izbire zdravstvenega delavca.
The telavancin medicinal product, which contains the excipient hydroxypropylbetadex (HP-β-CD), induced adverse effects in animal studies at plasma concentrations that were in the same range as clinical exposure levels and with possible relevance to clinical use.
Zdravilo telavancin, ki vsebuje pomožno snov hidroksipropilbetadeks (HP–β–CD), je sprožilo neželene učinke v študijah na živalih v plazemskih koncentracijah, ki so enake terapevtskim, zato lahko ima vpliv pri klinični uporabi.
The Temomedac dose may be adjusted, delayed or stopped depending on your blood counts and how you tolerate your medicine during each treatment cycle.
Odmerek zdravila Temomedac lahko prilagodijo, prestavijo ali zdravljenje prekinejo glede na vašo krvno sliko in na to, kako dobro prenašate zdravilo med vsakim ciklom zdravljenja.
The Temomedac dose may be delayed or stopped, depending on your blood counts and how you tolerate your medicine during the concomitant phase.
Odmerek zdravila Temomedac lahko prestavijo ali zdravljenje prekinejo glede na vašo krvno sliko in na to, kako dobro prenašate zdravilo med fazo sočasnega zdravljenja.
The Temozolomide Teva dose may be adjusted, delayed or stopped depending on your blood counts and how you tolerate your medicine during each treatment cycle.
To bo odvisno od vaše krvne slike in od tega, kako dobro boste prenašali zdravilo v vsakem ciklu zdravljenja.
The temperature of the suspension at the time of injection should be approximately 20 ºC-25 ºC. To re-suspend, vigorously roll the syringe between the palms until a uniform, cloudy suspension is achieved.
Temperatura suspenzije ob času injiciranja mora biti približno 20 °C – 25 °C. Za ponovno suspendiranje močno kotalite brizgo med dlanmi, da nastane enotna, motna suspenzija.
The temperature should then be increased to >39°C (but not exceeding 40°C) in two different sites of measurement in the tumour area.
Nato temperaturo povečamo do > 39°C (toda ne na več kot 40°C) na dveh različnih merilnih mestih v predelu tumorja.
The temporary usual signs following vaccination, such as increased temperature, apathy (listlessness) and digestive problems such as abdominal discomfort may also be seen following vaccination.
Po cepljenju se lahko pojavijo tudi prehodni običajni znaki, kot so: povišana temperatura, apatija (ravnodušnost), prebavne motnje, kot je neprijeten občutek v trebuhu.
The temsirolimus arm showed a 49% increase in median OS compared with the IFN-α arm.
Krak s temsirolimusom je pokazal 49-odstotno zvečanje medianega OS v primerjavi s krakom IFN-.
The teratogenic risk of GILENYA: the importance of avoiding pregnancy when undergoing treatment with GILENYA and the need for a negative pregnancy test result prior to treatment initiation.
Tveganje za teratogeno delovanje zdravila GILENYA: pomembnost preprečevanja zanositve v času zdravljenja z zdravilom GILENYA, pred začetkom zdravljenja pa je treba pridobiti negativen izvid testa nosečnosti.
The term "premalignant genital lesions" in section 4.1 corresponds to high-grade cervical intraepithelial neoplasia (CIN 2/3), high-grade vulvar intraepithelial neoplasia (VIN 2/3) and high- grade vaginal intraepithelial neoplasia (VaIN 2/3).
Izraz "predrakave genitalne lezije" v poglavju 4.1 predstavlja cervikalno intraepitelijsko neoplazijo visoke stopnje (CIN 2/3), intraepitelijsko neoplazijo visoke stopnje na vulvi (VIN 2/3) in intraepitelijsko neoplazijo visoke stopnje na nožnici (VaIN 2/3).
The term ‘hairy cell’ refers to the hair-like projections that can be seen on the surface of the lymphocytes when they are examined under a microscope.
Izraz „dlakavocelična” se nanaša na lasaste izrastke na površini limfocitov, ki so vidni pod mikroskopom.
The terminal elimination half- life (t1/2) is 5.4 hours.
Končni razpolovni čas izločanja (t1/2) je 5,4 ur.
The terminal elimination half-life (t1/2) is 5.4 hours.
Končni razpolovni čas izločanja (t1/2) je 5,4 ur.
The terminal elimination half-life (t1/2) is approximately 50 hours.
Terminalni eliminacijski razpolovni čas (t1/2) je pribliţno 50 ur.
The terminal elimination half-life averaged 23.7 hours (range 12 - 33).
Razpolovni čas popolne izločitve je bil v povprečju 23,7 ure (v intervalu 12 - 33).
The terminal elimination half-life is 11.7 hours after IV administration and 30.84 hours after single oral administration.
Končna razpolovna doba izločanja je 11,7 ure po intravenskem dajanju in 30,84 ure po enkratnem peroralnem odmerku.
The terminal elimination half-life is about 8 hours and steady-state concentrations of tolvaptan are obtained after the first dose.
Končni razpolovni čas izločanja je približno 8 ur in koncentracije v stanju dinamičnega ravnovesja tolvaptana so dosežene po prvem odmerku.
The terminal elimination half-life of hydrochlorothiazide is 10 – 15 hours.
Končna razpolovna doba izločanja je 10 do 15 ur.
The terminal half life ranged from 2.26 to 2.52 h.
Končni razpolovni čas je bil med 2,26 in 2,52 h.
The terminal half- life was estimated at 10 (+ 6) days.
Razpolovni čas je bil ocenjen na 10 (+6) dni.
The terminal half-life (t½) is therefore a measure of the absorption rather than of the elimination per se of insulin from plasma (insulin in the blood stream has a t½ of a few minutes).
Terminalni razpolovni cas (t1/2) je torej merilo absorpcije, ne izlocanja insulina iz plazme per se (insulin v krvnem obtoku ima t1/2 nekaj minut).
The terminal half-life and renal clearance of dabigatran were not affected by dronedarone.
Dronedaron ni vpliva na končno razpolovno dobo in ledvični očistek dabigatrana.
The terminal half-life at the maximum tolerated intravenous dose (150 µg/m2) was 15-30 min.
Končna razpolovna doba je bila 15 do 30 minut pri največjem intravenskem odmerku, ki so ga bolniki še lahko prenesli (150 µg/m2).
The terminal half-life decreased by about 50-60%.
Končna razpolovna doba se je zmanjšala za približno 50-60 %.
The terminal half-life in stable renal transplant patients after multiple oral doses was 62  16 hours.
Biološka razpolovna doba v končni fazi eliminacije pri stabilnih bolnikih po presaditvi ledvice po večkratnih peroralnih odmerkih znaša 62 ± 16 ur.
The terminal half-life in stable renal transplant patients after multiple oral doses was 6216h.
Biološka razpolovna doba v končni fazi eliminacije pri stabilnih bolnikih po presaditvi ledvice po večkratnih peroralnih odmerkih znaša 62 ± 16 ur.
The terminal half-life is determined by the rate of absorption from the subcutaneous tissue.
Terminalni razpolovni cas je dolocen s hitrostjo absorpcije iz podkožnega tkiva.
The terminal half-life may not only reflect the elimination phase of the compound, but may also reflect the sustained absorption of Pegasys.
Končna razpolovna doba lahko kaže na fazo izločanja učinkovine in zapoznelo absorpcijo zdravila Pegasys.
The terminal half-life of the active metabolite following oral administration is approximately 7 hours and is absorption rate-limited.
Po peroralni uporabi je končni razpolovni čas aktivnega presnovka približno 7 ur in je omejen s hitrostjo absorbcije.
The terminal half-life ranged from 14.5 to 44.8 hr with a mean of 23.3  8.0 (n=14, CV=34%) and a median of 21.2 hr.
Končni razpolovni čas je bil od 14,5 do 44,8 h, s povprečno vrednostjo 23,3  8,0 (n = 14, koeficient variacije = 34 %) in mediano 21,2 h.
The terminal half-life ranged from 2.8 to
Končni razpolovni čas je bil med 2,8 in 3,9 ure.
The terminal half-lives for the elimination of tylvalosin and its active metabolite 3-AT range from 1 to
Končni razpolovni čas izločanja tilvalozina in njegovega aktivnega presnovka 3-AT je med 1 in 1,45 ur.
The terminal half-lives for the elimination of tylvalosin and its active metabolite 3-AT range from 1 to
Terminalna razpolovna časa tilvalozina in njegovega aktivnega presnovka 3-AT sta od 1 do 1,45 ure.
The terminal intracellular half-life of lamivudine-TP was prolonged to 16-19 hours, compared to the plasma lamivudine half-life of 5-7 hours, supporting once daily dosing of ABC and 3TC.
Končni znotrajcelični razpolovni čas lamivudina-TP je bil podaljšan na 16–19 ur, v primerjavi z razpolovnim časom lamivudina v plazmi, ki je bil 5–7 ur, kar podpira odmerjanje ABC in 3TC enkrat dnevno.
The terminal plasma half-life is about 1-2 hours.
Končna razpolovna doba v plazmi je približno 1–2 uri.
The test begins with the collection of samples for determining the baseline values:
Test se prične z zbiranjem vzorcev za določanje začetnih vrednosti.
The test is to be performed after instruction by a healthcare professional and under appropriate medical supervision.
Zdravilo sme dajati samo strokovni zdravstveni delavec, sme pa se dajati samo pod ustreznim zdravniškim nadzorom.
The test is to be performed in the presence of a qualified person.
Test morate opraviti v prisotnosti usposobljene osebe.
The test meal is not provided within the kit.
Ta obrok ni priložen v testnem kompletu.
The test method for HER2 overexpression used to determine eligibility of patients in the pivotal Herceptin monotherapy and Herceptin plus paclitaxel clinical trials employed immunohistochemical staining for HER2 of fixed material from breast tumours using the murine monoclonal antibodies CB11 and 4D5.
Testna metoda za določanje čezmerno izraženega HER2, s katero ugotovijo primernost bolnika, ki so jo uporabili v ključnih kliničnih preskušanjih monoterapije zdravila Herceptin in zdravila Herceptin z docetakselom, temelji na imunohistokemičnem barvanju HER2 v fiksiranih preparatih tumorjev dojk po uporabi murinih monoklonskih protiteles CB11 in 4D5.